

**Date and Time:** *Thursday 26 March 2015, 10am-4.00 pm*

**Minutes:** Confirmed

**Cirrhosis Guideline Development Group Meeting 7**

**Place:** *Sloane Room, Royal College of Physicians, 11 St Andrews Place, Regent's Park, London NW1 4LE*

<b>Present:</b>	Phil Harrison (Chair)	Consultant Hepatologist
	Marsha Morgan	Principle Research Fellow/Honorary Consultant Physician
	Susan McRae	Patient/Carer Member
	Andrew Fowell	Consultant Gastroenterologist and Hepatologist
	Lynda Greenslade	Clinical Nurse Specialist in Hepatology
	Valerie Ross	Lead Pharmacist, Hepatology
	Mark Hudson	Consultant Hepatologist
	Iain Brew	General Practitioner
	Gerri Mortimore	Lead CNS Liver
	Andrew Langford	Patient/Carer Member
	Philip Johnson (co-optee)	Consultant Hepatologist/Oncologist
	Emily Davies	Senior Research Fellow, NCGC
	Gill Ritchie	Associate Director, NCGC
	Katie Jones	Project Manager, NCGC
	Brian Hogan	Specialist Registrar in Hepatology and Intensive Medicine
	Stacey Lockyer	Research Fellow, NCGC
	Leteris Floros	Health Economist, NCGC
	Martin J Harker	Senior Health Economist, NCGC

**In attendance:**

NICE Staff: Caroline Keir Sarah Palombella		
--	--	--

**Apologies:**

Ben Pordes, Project Manager, NCGC

Jill Cobb, Information Scientist, NCGC

**Notes**

1. The Chair welcomed the group to the sixth meeting of this GDG. Apologies were received from BP and JC. The Chair reviewed and requested updates to the declarations of interest register. The Chair declared that in relation to the **previous** declarations recorded in the DOI register, for this meeting, no action was required.

**New** declarations of interest received for this GDG meeting include:

GDG Declarations of Interest			
N.B. The Chair and GDG members were recruited to this guideline using NICE DOI policy published Oct 2008.			
Insert initials	Declaration	Classification	Chairs action

		(as per the NICE DOI policy wording*)	
LG	Funding for travel and accommodation had been received from Jansen to attend EASL conference 2015.	Personal financial non-specific	Declare and participate
AF	Funding for travel and accommodation had been received for Jansen to attend a conference in 2015.	Personal financial non-specific	Declare and participate
PJ	Funding from Wako Life Sciences, who make liver screening tests provided travel expenses to attend a AASLD meeting.	Personal specific non-pecuniary interest	Declare and participate (as a co-optee).
VR	Funding for travel and accommodation received from Abbvie to attend EASL conference in April 2015.  Attended an advisory board for AbbVie.	Personal non-specific pecuniary interest  Personal non-specific pecuniary interest	Personal non-specific pecuniary interest  Personal non-specific pecuniary interest

2. The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.
3. The Linking Evidence to Recommendations documents from GDG6 (risk factors for cirrhosis and IV albumin for hepatorenal syndrome) were reviewed and agreed.
4. PJ introduced the topic of hepatocellular carcinoma (HCC) surveillance.
5. ED presented the clinical evidence report for HCC surveillance. LF presented the health economic evidence.
6. ED presented the clinical evidence report for surveillance for varices. LF presented the health economic evidence.
7. The protocol for vasoactive drugs for hepatorenal syndrome was presented and discussed.
8. SP presented to the GDG on writing for NICE.
9. LF presented to the GDG on details of the economic model.
10. There was no other business.

**Date, time and venue of the next meeting**

**GDG8:** Thursday 30 April 2015; Rosenheim and Pickering room, 11 St Andrews Place, Regent's Park, London NW1 4LE; 10am-4pm